CLPT ClearPoint Neuro Inc

  1. Stocks
  2. Healthcare
  3. NYSEAMERICAN: CLPT

Price (delayed)

$5.87

Market cap

$158.35M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.9

Enterprise value

$149.15M

ClearPoint Neuro's mission is to improve and restore quality of life to patients and their families by enabling therapies for the most complex neurological disorders with pinpoint accuracy. Applications of ...

Highlights
ClearPoint Neuro's revenue has increased by 17% YoY and by 7% from the previous quarter
The gross profit has grown by 5% from the previous quarter
The equity has contracted by 43% YoY and by 12% from the previous quarter
The quick ratio has contracted by 40% YoY and by 26% from the previous quarter
Sector: Healthcare
Industry: Medical Devices
Website: http://www.clearpointneuro.com
Peers: CHGG MMYT TRIP

Key stats

What are the main financial stats of CLPT
Market
Shares outstanding
26.98M
Market cap
$158.35M
Enterprise value
$149.15M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
6.83
Price to sales (P/S)
6.03
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.23
Earnings
Revenue
$23.96M
EBIT
-$22.48M
EBITDA
-$21.02M
Free cash flow
-$14.77M
Per share
EPS
-$0.9
Free cash flow per share
-$0.6
Book value per share
$0.86
Revenue per share
$0.97
TBVPS
$1.68
Balance sheet
Total assets
$42.66M
Total liabilities
$21.49M
Debt
$13.94M
Equity
$21.17M
Working capital
$28.74M
Liquidity
Debt to equity
0.66
Current ratio
4.87
Quick ratio
3.55
Net debt/EBITDA
0.44
Margins
EBITDA margin
-87.7%
Gross margin
56.8%
Net margin
-92.2%
Operating margin
-93.7%
Efficiency
Return on assets
-47.9%
Return on equity
-83.9%
Return on invested capital
-80.4%
Return on capital employed
-63.8%
Return on sales
-93.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CLPT stock price

How has the ClearPoint Neuro stock price performed over time
Intraday
6.34%
1 week
11.6%
1 month
-11.06%
1 year
-37.15%
YTD
-13.55%
QTD
-13.68%

Financial performance

How have ClearPoint Neuro's revenue and profit performed over time
Revenue
$23.96M
Gross profit
$13.61M
Operating income
-$22.45M
Net income
-$22.09M
Gross margin
56.8%
Net margin
-92.2%
The company's operating income fell by 37% YoY
ClearPoint Neuro's net income has decreased by 34% YoY
ClearPoint Neuro's operating margin has decreased by 18% YoY but it has increased by 6% from the previous quarter
ClearPoint Neuro's revenue has increased by 17% YoY and by 7% from the previous quarter

Growth

What is ClearPoint Neuro's growth rate over time

Valuation

What is ClearPoint Neuro stock price valuation
P/E
N/A
P/B
6.83
P/S
6.03
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.23
ClearPoint Neuro's EPS has decreased by 32% YoY
The P/B is 85% below the 5-year quarterly average of 45.6 but 5% above the last 4 quarters average of 6.5
The equity has contracted by 43% YoY and by 12% from the previous quarter
The price to sales (P/S) is 51% lower than the 5-year quarterly average of 12.3 and 22% lower than the last 4 quarters average of 7.7
ClearPoint Neuro's revenue has increased by 17% YoY and by 7% from the previous quarter

Efficiency

How efficient is ClearPoint Neuro business performance
The return on equity has dropped by 111% year-on-year and by 16% since the previous quarter
CLPT's ROA has plunged by 72% YoY and by 8% from the previous quarter
ClearPoint Neuro's return on invested capital has shrunk by 69% YoY and by 8% QoQ
ClearPoint Neuro's ROS has decreased by 18% YoY but it has increased by 6% from the previous quarter

Dividends

What is CLPT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CLPT.

Financial health

How did ClearPoint Neuro financials performed over time
The company's total assets is 99% higher than its total liabilities
The quick ratio has contracted by 40% YoY and by 26% from the previous quarter
The current ratio has contracted by 35% YoY and by 27% from the previous quarter
CLPT's debt is 34% lower than its equity
The debt to equity has surged by 106% year-on-year and by 14% since the previous quarter
The equity has contracted by 43% YoY and by 12% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.